Learn more
Join Dexa

Cardiac Safety Insights

The conversation dives into the safety profile of psychedelics, particularly regarding potential cardiac risks associated with microdosing. Insights highlight the importance of comparing risks, especially in contexts of addiction and overdose. The discussion also touches on FDA guidance concerning cardiac valve issues linked to classic psychedelics and the ongoing efforts to modify molecules like ibogaine to mitigate these risks.